Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 21 | 2015 | 326 | 2.420 |
Why?
|
| Kidney Diseases | 10 | 2010 | 177 | 1.940 |
Why?
|
| Immunosuppressive Agents | 7 | 2015 | 380 | 1.030 |
Why?
|
| Kidney Failure, Chronic | 4 | 2015 | 196 | 0.900 |
Why?
|
| Sirolimus | 4 | 2015 | 93 | 0.860 |
Why?
|
| Polyomavirus Infections | 10 | 2009 | 31 | 0.810 |
Why?
|
| Graft Rejection | 7 | 2015 | 302 | 0.760 |
Why?
|
| Calcineurin Inhibitors | 3 | 2015 | 22 | 0.660 |
Why?
|
| BK Virus | 6 | 2009 | 23 | 0.650 |
Why?
|
| Postoperative Complications | 8 | 2015 | 1314 | 0.640 |
Why?
|
| Transplantation, Homologous | 10 | 2009 | 250 | 0.580 |
Why?
|
| Tumor Virus Infections | 4 | 2007 | 26 | 0.490 |
Why?
|
| Graft Survival | 5 | 2018 | 297 | 0.470 |
Why?
|
| Paraplegia | 1 | 2015 | 7 | 0.460 |
Why?
|
| Enterovirus Infections | 1 | 2015 | 12 | 0.460 |
Why?
|
| Enterovirus D, Human | 1 | 2015 | 11 | 0.460 |
Why?
|
| Brain Diseases | 1 | 2015 | 76 | 0.430 |
Why?
|
| Cardiovascular Diseases | 3 | 2010 | 862 | 0.340 |
Why?
|
| Propanolamines | 1 | 2010 | 10 | 0.330 |
Why?
|
| Carbazoles | 1 | 2010 | 13 | 0.330 |
Why?
|
| Heart Failure, Systolic | 1 | 2010 | 16 | 0.330 |
Why?
|
| Hypertension | 2 | 2010 | 610 | 0.330 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2010 | 152 | 0.310 |
Why?
|
| Aspirin | 1 | 2010 | 171 | 0.300 |
Why?
|
| Chronic Disease | 6 | 2010 | 741 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 4 | 2010 | 120 | 0.290 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2010 | 233 | 0.280 |
Why?
|
| Risk Reduction Behavior | 1 | 2009 | 121 | 0.280 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2010 | 168 | 0.280 |
Why?
|
| Calciphylaxis | 1 | 2008 | 10 | 0.270 |
Why?
|
| Skin Ulcer | 1 | 2008 | 14 | 0.270 |
Why?
|
| Protein Kinases | 1 | 2008 | 152 | 0.270 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 198 | 0.260 |
Why?
|
| Creatinine | 5 | 2010 | 135 | 0.250 |
Why?
|
| Biopsy | 9 | 2008 | 454 | 0.240 |
Why?
|
| Humans | 33 | 2018 | 64914 | 0.200 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2015 | 800 | 0.190 |
Why?
|
| Pancreas Transplantation | 2 | 2018 | 19 | 0.190 |
Why?
|
| AIDS-Associated Nephropathy | 2 | 2000 | 9 | 0.180 |
Why?
|
| Mycophenolic Acid | 2 | 2015 | 68 | 0.170 |
Why?
|
| Treatment Failure | 4 | 2009 | 206 | 0.170 |
Why?
|
| Middle Aged | 12 | 2015 | 18170 | 0.170 |
Why?
|
| Anti-HIV Agents | 2 | 2006 | 139 | 0.150 |
Why?
|
| Liver Circulation | 1 | 2018 | 11 | 0.140 |
Why?
|
| Mesenteric Veins | 1 | 2018 | 11 | 0.140 |
Why?
|
| Femoral Vein | 1 | 2018 | 19 | 0.140 |
Why?
|
| Primary Prevention | 2 | 2010 | 136 | 0.140 |
Why?
|
| Portal Vein | 1 | 2018 | 39 | 0.140 |
Why?
|
| Kidney | 4 | 2007 | 451 | 0.140 |
Why?
|
| Vena Cava, Inferior | 1 | 2018 | 33 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2018 | 37 | 0.140 |
Why?
|
| Male | 14 | 2018 | 30904 | 0.130 |
Why?
|
| Risk Factors | 5 | 2018 | 5404 | 0.130 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 460 | 0.130 |
Why?
|
| Heart Failure | 1 | 2005 | 949 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2015 | 31 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2018 | 5776 | 0.110 |
Why?
|
| Alemtuzumab | 1 | 2015 | 11 | 0.110 |
Why?
|
| Azathioprine | 1 | 2015 | 27 | 0.110 |
Why?
|
| Everolimus | 1 | 2015 | 22 | 0.110 |
Why?
|
| Acute Disease | 2 | 2015 | 664 | 0.110 |
Why?
|
| Abatacept | 1 | 2015 | 67 | 0.110 |
Why?
|
| Tacrolimus | 1 | 2015 | 63 | 0.110 |
Why?
|
| Cyclosporine | 1 | 2015 | 77 | 0.110 |
Why?
|
| Pyrroles | 1 | 2015 | 49 | 0.110 |
Why?
|
| Bone Marrow Transplantation | 1 | 2015 | 140 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2015 | 74 | 0.110 |
Why?
|
| Piperidines | 1 | 2015 | 74 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2009 | 2483 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2015 | 146 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2015 | 162 | 0.100 |
Why?
|
| Adult | 8 | 2018 | 17279 | 0.100 |
Why?
|
| Nephritis | 2 | 2003 | 11 | 0.100 |
Why?
|
| Amyloidosis | 2 | 2006 | 68 | 0.100 |
Why?
|
| Heart Transplantation | 1 | 2015 | 180 | 0.100 |
Why?
|
| HIV-1 | 1 | 1998 | 705 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 249 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 803 | 0.090 |
Why?
|
| Female | 10 | 2018 | 33873 | 0.090 |
Why?
|
| Time Factors | 5 | 2018 | 3755 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1557 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2002 | 20 | 0.090 |
Why?
|
| Isoenzymes | 2 | 2002 | 129 | 0.080 |
Why?
|
| Prognosis | 1 | 2015 | 1775 | 0.080 |
Why?
|
| Atrophy | 2 | 2008 | 87 | 0.080 |
Why?
|
| Maryland | 3 | 2005 | 36 | 0.080 |
Why?
|
| Double-Blind Method | 1 | 2010 | 740 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2010 | 278 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 146 | 0.070 |
Why?
|
| Calcineurin | 1 | 2008 | 48 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2009 | 989 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 845 | 0.070 |
Why?
|
| Secondary Prevention | 1 | 2009 | 164 | 0.070 |
Why?
|
| Embolism, Cholesterol | 1 | 2008 | 3 | 0.070 |
Why?
|
| Fibrosis | 1 | 2008 | 172 | 0.070 |
Why?
|
| Buttocks | 1 | 2008 | 9 | 0.070 |
Why?
|
| Polyomavirus | 2 | 2004 | 12 | 0.070 |
Why?
|
| Thigh | 1 | 2008 | 27 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2008 | 132 | 0.070 |
Why?
|
| JC Virus | 1 | 2007 | 23 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2007 | 231 | 0.070 |
Why?
|
| Kidney Function Tests | 1 | 2007 | 36 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 2284 | 0.060 |
Why?
|
| Recurrence | 1 | 2009 | 655 | 0.060 |
Why?
|
| Nephrosis | 1 | 2006 | 4 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 294 | 0.060 |
Why?
|
| Patient Selection | 1 | 2009 | 483 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 176 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2238 | 0.060 |
Why?
|
| Virus Replication | 1 | 2007 | 323 | 0.060 |
Why?
|
| Kidney Glomerulus | 2 | 2002 | 23 | 0.060 |
Why?
|
| Histocompatibility Testing | 1 | 2005 | 32 | 0.060 |
Why?
|
| Radionuclide Ventriculography | 1 | 2005 | 5 | 0.060 |
Why?
|
| Kidney Cortex | 1 | 2004 | 10 | 0.060 |
Why?
|
| Systole | 1 | 2005 | 109 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 2 | 2002 | 61 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2006 | 142 | 0.050 |
Why?
|
| Aged | 4 | 2010 | 14884 | 0.050 |
Why?
|
| Animals | 3 | 2015 | 21347 | 0.050 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 554 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2005 | 191 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2005 | 251 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2005 | 575 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2002 | 204 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2010 | 2092 | 0.050 |
Why?
|
| Stroke Volume | 1 | 2005 | 342 | 0.050 |
Why?
|
| Reoperation | 1 | 2004 | 300 | 0.050 |
Why?
|
| Pancreas | 1 | 2003 | 154 | 0.050 |
Why?
|
| Mushroom Poisoning | 1 | 2002 | 1 | 0.050 |
Why?
|
| Sulfasalazine | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2002 | 22 | 0.050 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2002 | 12 | 0.050 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 6 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 29 | 0.050 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2002 | 33 | 0.040 |
Why?
|
| United States | 2 | 2009 | 8065 | 0.040 |
Why?
|
| Organophosphonates | 1 | 2002 | 22 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 68 | 0.040 |
Why?
|
| Cytosine | 1 | 2002 | 31 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 94 | 0.040 |
Why?
|
| Interferons | 1 | 2002 | 73 | 0.040 |
Why?
|
| Urine | 3 | 2009 | 45 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 130 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2000 | 17 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2002 | 224 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 58 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2018 | 6824 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2002 | 133 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2000 | 62 | 0.040 |
Why?
|
| HIV Infections | 1 | 2006 | 956 | 0.040 |
Why?
|
| Stavudine | 1 | 1998 | 3 | 0.040 |
Why?
|
| Lamivudine | 1 | 1998 | 7 | 0.040 |
Why?
|
| Nelfinavir | 1 | 1998 | 7 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2004 | 513 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2000 | 321 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2000 | 219 | 0.040 |
Why?
|
| Cytokines | 1 | 2002 | 959 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 922 | 0.030 |
Why?
|
| Schizophrenia | 1 | 1998 | 275 | 0.030 |
Why?
|
| Incidence | 3 | 2007 | 1412 | 0.030 |
Why?
|
| Prevalence | 1 | 1999 | 1438 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 881 | 0.030 |
Why?
|
| Viral Load | 2 | 2004 | 231 | 0.030 |
Why?
|
| Living Donors | 2 | 2005 | 79 | 0.020 |
Why?
|
| Kidney Tubules | 2 | 2003 | 23 | 0.020 |
Why?
|
| Mutation | 1 | 2000 | 2659 | 0.020 |
Why?
|
| Adolescent | 2 | 2018 | 6283 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4783 | 0.020 |
Why?
|
| Syndrome | 1 | 2008 | 178 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 112 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2006 | 123 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2005 | 62 | 0.010 |
Why?
|
| Base Sequence | 1 | 2007 | 1329 | 0.010 |
Why?
|
| Viremia | 1 | 2004 | 46 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 1985 | 0.010 |
Why?
|
| Simian virus 40 | 1 | 2003 | 17 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 2003 | 65 | 0.010 |
Why?
|
| Sclerosis | 1 | 2003 | 10 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2004 | 315 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 253 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 148 | 0.010 |
Why?
|
| Control Groups | 1 | 2002 | 13 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2003 | 178 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2003 | 282 | 0.010 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2002 | 4 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 37 | 0.010 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2002 | 25 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 2002 | 33 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 94 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2007 | 2609 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 507 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2008 | 918 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2000 | 26 | 0.010 |
Why?
|
| Azoxymethane | 1 | 2000 | 15 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 2000 | 56 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 2000 | 9 | 0.010 |
Why?
|
| Carcinogens | 1 | 2000 | 33 | 0.010 |
Why?
|
| Genes, ras | 1 | 2000 | 28 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2002 | 326 | 0.010 |
Why?
|
| beta Catenin | 1 | 2000 | 99 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2007 | 3303 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2003 | 632 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 392 | 0.010 |
Why?
|
| Child | 1 | 2009 | 4603 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 323 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2001 | 1103 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 1095 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 5583 | 0.010 |
Why?
|
| Disease Progression | 1 | 2001 | 1214 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2001 | 1690 | 0.010 |
Why?
|
| Rats | 1 | 2000 | 1995 | 0.010 |
Why?
|
| Inflammation | 1 | 2001 | 1191 | 0.010 |
Why?
|